Adagio Medical (ADGM) Projected to Release Quarterly Earnings on Wednesday

Adagio Medical (NASDAQ:ADGM) is expected to be posting its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Adagio Medical (NASDAQ:ADGM) last posted its earnings results on Tuesday, May 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02). On average, analysts expect Adagio Medical to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Adagio Medical Trading Down 22.0%

Shares of Adagio Medical stock opened at $0.62 on Wednesday. The stock has a market capitalization of $13.86 million, a P/E ratio of -0.41 and a beta of -0.15. The company has a quick ratio of 1.66, a current ratio of 1.85 and a debt-to-equity ratio of 4.00. The company has a 50-day simple moving average of $0.62 and a 200 day simple moving average of $0.92. Adagio Medical has a 12-month low of $0.36 and a 12-month high of $2.58.

Institutional Trading of Adagio Medical

A number of institutional investors have recently bought and sold shares of ADGM. Perceptive Advisors LLC boosted its position in shares of Adagio Medical by 0.7% in the 2nd quarter. Perceptive Advisors LLC now owns 9,876,576 shares of the company’s stock worth $12,840,000 after purchasing an additional 64,157 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Adagio Medical by 18.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,258,501 shares of the company’s stock valued at $1,309,000 after acquiring an additional 200,000 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Adagio Medical during the 4th quarter worth approximately $1,206,000. ADAR1 Capital Management LLC acquired a new stake in shares of Adagio Medical in the fourth quarter valued at approximately $1,206,000. Finally, Armistice Capital LLC acquired a new position in Adagio Medical during the fourth quarter worth $497,000. Institutional investors and hedge funds own 48.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Zacks Research raised shares of Adagio Medical to a “hold” rating in a report on Wednesday, April 15th. Weiss Ratings lowered Adagio Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, July 20th. Finally, Piper Sandler assumed coverage on Adagio Medical in a research note on Tuesday, April 14th. They issued an “overweight” rating and a $3.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $3.50.

Adagio Medical Company Profile

Adagio Medical, Inc (NASDAQ: ADGM) is a medical device company focused on the development and commercialization of a noninvasive system for monitoring intracranial pressure (ICP). The company’s proprietary technology uses tympanic membrane displacement to provide clinicians with real-time estimates of ICP without the risks associated with invasive catheter methods. This approach is designed to improve patient safety, reduce complications, and streamline neurological monitoring in acute and critical care settings.

At the core of Adagio Medical’s pipeline is its ADGM System, which is intended for use in hospitals, emergency departments, and other clinical environments where rapid and accurate assessment of ICP is crucial.